Sugi Predict

Sugi Predict / Compounds / SCHEMBL1300573

SCHEMBL1300573

SCHEMBL1300573

Cc1c(F)c2c(c(OCc3ccccc3)c1C(=O)Oc1ccccc1)CNC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.40
▸ MAOB P27338 2/20 0.37
▸ LMNA P02545 3/20 0.37
▸ HPGD P15428 1/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ KMT2A Q03164 1/20 0.36
▸ NR4A1 P22736 1/20 0.36
▸ NR4A2 P43354 1/20 0.36
▸ NR4A3 Q92570 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ PPARG P37231 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1299609 0.92 CHRM2 (0.38) PTPN1LMNAHPGDNPC1RAB9A
SCHEMBL1300094 0.92 CHRM2 (0.38) PTPN1MAOBLMNAHPGDNPC1
SCHEMBL1300118 0.88 PTPN1 (0.40) PTPN1MAOBLMNAHPGDUSP2
SCHEMBL1300807 0.87 PTPN1 (0.38) PTPN1MAOBLMNAHPGDUSP2
SCHEMBL12281423 0.87 FAAH (0.38) LMNANPC1SMN1; SMN2KMT2ATSHR
SCHEMBL1300319 0.87 PTPN1 (0.40) PTPN1MAOBLMNAHPGDNPC1
SCHEMBL17692764 0.86 PTPN1 (0.43) PTPN1MAOBLMNAHPGD
SCHEMBL1299606 0.85 PTPN1 (0.38) PTPN1MAOBLMNAHPGDUSP2
SCHEMBL12108726 0.84 PTPN1 (0.39) PTPN1MAOBLMNAHPGDRAB9A
SCHEMBL20370139 0.83 PTPN1 (0.45) PTPN1MAOBLMNAHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170107179-A1 Polycyclic Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2017-04-20 — — US disclosed
EP-2552890-B1 POLYCYCLIC TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2017-01-04 — — EP disclosed
US-9371283-B2 Polycyclic tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2016-06-21 — — US disclosed
EP-2552890-A1 POLYCYCLIC TETRACYCLINE COMPOUNDS Tetraphase Pharmaceuticals, Inc. (US) 2013-02-06 — — EP disclosed
US-20110269714-A1 Polycyclic Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2011-11-03 — — US disclosed
WO-2011123536-A1 POLYCYCLIC TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. (US) 2011-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170107179-A1 Polycyclic Tetracycline Compounds TET1, TUBA1C, TUBB PTPN1 470/4885MAOB 2325/4885LMNA 2586/4885
US-20110269714-A1 Polycyclic Tetracycline Compounds TET1, TUBA1C, TUBB PTPN1 470/4885MAOB 2325/4885LMNA 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.